Previous Article | Next Article 
Journal of Clinical Microbiology, July 1998, p. 2023-2029, Vol. 36, No. 7
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Comparison of Roche Cobas Amplicor Mycobacterium
tuberculosis Assay with In-House PCR and Culture for Detection
of M. tuberculosis
Bodo R.
Eing,*
Andrea
Becker,
Arthur
Sohns, and
Ronald
Ringelmann
Institut für Medizinische Mikrobiologie
und Immunologie, Städtisches Klinikum Karlsruhe, 76133 Karlsruhe,
Germany
Received 23 December 1997/Returned for modification 4 February
1998/Accepted 21 April 1998
 |
ABSTRACT |
The new Roche Cobas Amplicor Mycobacterium tuberculosis
assay, which is a semiautomated version of the manually performed Roche
Amplicor M. tuberculosis test, was compared to culture and an IS6110-based in-house PCR protocol. A total of 1,681 specimens from 833 patients, including specimen types other than
sputum, were tested in parallel by both the in-house PCR and the Cobas Amplicor M. tuberculosis assay. After we resolved
discrepant PCR results, the sensitivity, specificity, and positive and
negative predictive values for the Cobas Amplicor M. tuberculosis assay were 66.33, 99.71, 94.36, and 97.66%,
respectively. The corresponding values for the in-house PCR were 91.08, 99.85, 97.87, and 99.37%, respectively. For culture- and
smear-positive specimens, the sensitivity of the Cobas Amplicor
M. tuberculosis test was 96.42% (in-house PCR, 100%). If
only smear-negative sputum specimens were considered, the Cobas
Amplicor M. tuberculosis assay exhibited a sensitivity of
45.45% (in-house PCR, 63.63%) relative to that of culture. With a
modified protocol for DNA extraction (washing of samples plus
ultrasonication), both PCR methods performed better with gastric
aspirates than with sputum samples (sensitivity of the Cobas Amplicor
M. tuberculosis assay with smear-negative gastric aspirates, 70.00%; sensitivity of in-house PCR, 90.00%). With dithiothreitol being used for liquefaction of specimens in this study,
the Cobas Amplicor M. tuberculosis assay exhibited an
inhibition rate of 9.16%. In our view, the new Cobas Amplicor M. tuberculosis test (i) is well suited for typing of smear-positive
specimens, (ii) may also be applied to gastric aspirates and other
types of specimens if DNA extraction methods are modified
appropriately, and (iii) exhibits a sensitivity with smear-negative
sputum specimens which makes it recommendable that a minimum of three
samples from the same patient be tested.
 |
INTRODUCTION |
Since the beginning of this decade,
PCR and other amplification techniques have been introduced into the
diagnosis of infections with Mycobacterium tuberculosis
(1, 6, 9, 14-16, 22, 25, 26). Although no amplification
system known today provides sufficient sensitivity to replace culture
as a reliable screening tool, an increasing number of diagnostic
laboratories have established amplification techniques as supplementory
tests, because they provide good rates of positive results with better
turnaround times than culture (days versus weeks) and they can specify
positive smear results. The latter feature is essential for
laboratories dealing with a high portion of infections with
mycobacteria other than M. tuberculosis (MOTT)
(9). Because establishing and maintaining in-house protocols
for any amplification method requires highly specialized personnel and
enormous logistic efforts to control the well-known contamination
problem, there is an obvious need of commercially available,
easy-to-use diagnostic kits which have the potential of automation. To
date, a few diagnostic tests for detection of M. tuberculosis in clinical specimens after DNA or RNA amplification
have been marketed. Of these, the Roche Diagnostics (Grenzach-Whylen,
Germany) Cobas Amplicor M. tuberculosis test (CA) exhibits
the highest degree of automation. The CA amplifies, hybridizes, and
detects amplicons in one run without the need of any manual
intervention and offers the possibility of processing PCR mixtures for
different targets in parallel. The aim of this study was to evaluate
this new test system by comparing it to culture and an in-house PCR
protocol. In addition, we tested the CA with specimen types other than
sputum and evaluated the diagnostic value of the PCR techniques
investigated in this study in a case-oriented fashion.
 |
MATERIALS AND METHODS |
Clinical specimens.
All specimens submitted to our
institution for diagnosis of tuberculosis (TB) from January to November
1996 were examined in parallel by conventional analysis (fluorochrome
stain and culture; see below) and PCR (CA and in-house PCR; see below).
The following restrictions applied: (i) if the actual work load
exceeded the capacities of the PCR working group, PCR was performed on
a subset of specimens which guaranteed that at least one specimen per
patient was examined by both PCR methods, (ii) only one smear-positive specimen per smear-positive patient was tested in order to minimize the
input of genomic DNA into the DNA extraction area, (iii) small-volume specimens were tested only by conventional methods, and (iv) stool and
blood samples were not examined by either PCR system. Specimens inhibitory to CA were not included for calculation of sensitivity, specificity, and predictive values.
Specimen processing for conventional analysis.
Sputa were
mechanically homogenized and liquified with 1 volume of 0.1% (wt/vol)
dithiothreitol (DTT) in distilled water. The liquified material was
split for further separate processing by conventional analysis and PCR
(approximately 1 ml for each method). Subsequently, bacteria were
sedimented in a refrigerated centrifuge at 4,500 × g
for 10 min. A loopful of the resulting pellet was used to prepare a
slide for acid-fast staining, and the remaining material was further
processed by the Zephirol-trisodium phosphate method for
decontamination (23). After neutralization, the suspension
was centrifuged at 4,500 × g for 10 min and
resuspended in 1 ml of distilled water. Urine and other liquid samples
were centrifuged at 4,500 × g for 10 min, and the
resulting pellets were treated as described above for sputum sediments
after liquefaction. Swab samples were squeezed into sterile distilled
water and centrifuged; the sediment was treated as described above.
Cerebrospinal fluid was concentrated only by centrifugation; there was
no further treatment. Biopsy samples were mechanically homogenized, and
the homogenate was directly inoculated onto culture media. If the presence of a contaminating flora was expected (e.g., in biopsies from
abscess walls), the homogenate was decontaminated and neutralized as
described above. The numbers of each specimen type studied are given in
the first row of Table 5.
Smear examination.
Acid-fast stains of the homogenized
specimens were prepared with auramine-rhodamine and Ziehl-Neelsen stain
and examined according to standard procedures (23). Urine
samples were examined by microscopy only if urogenital TB was
suspected.
Culture and identification.
After decontamination as
described above, 0.2 ml of the resulting suspension was inoculated into
one BACTEC 12B bottle (Becton Dickinson, Heidelberg, Germany)
supplemented according to the manufacturer's instructions, 0.2 ml was
inoculated onto one Stonebrink slant (Becton Dickinson), and 0.2 ml was
inoculated into 2 ml of brain heart infusion broth as a contamination
control. Since July 1996, MGIT fluorescent liquid medium (Becton
Dickinson) has been used instead of the BACTEC system. All culture
media were read twice weekly; all cultures suspected of growth were
immediately examined by acid-fast staining, the
p-nitro-acetylamino-hydroxy-propiophenon (NAP) test, and a
PCR-restriction fragment length polymorphism technique suited for
typing of mycobacteria (28). In addition, all isolates were
identified to species level by standard techniques (23).
Specimen processing for in-house PCR.
After homogenization
and centrifugation, sediments were washed twice with an equal volume of
Tris-EDTA buffer (10 mM Tris-HCl [pH 8.0], 0.5 mM EDTA) at
16,000 × g for 5 min. The resulting pellet was
resuspended in an equal volume of Tris-EDTA buffer and subjected to 5 min of ultrasonication in an ultrasonication water bath (80 W). The
sample was then boiled for 10 min, chilled on ice, and centrifuged at
16,000 × g for 10 min, and 5 µl of the supernatant
was analyzed by PCR in a 50-µl reaction mixture (see below).
DNAs from biopsy samples were extracted with a DNA tissue extraction
kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions except that the sample was sonicated in the protease digestion mixture as described above. The resulting eluate was heated
to 100°C for 10 min and chilled on ice, and 5 µl was used as input
for a 50-µl PCR mixture.
Specimen processing for CA.
A portion (0.1 ml) of the sample
as obtained after liquefaction was washed and further processed by
alkaline lysis as recommended by the manufacturer with the reagents
provided in the sample preparation kit. For biopsy samples, DNAs were
extracted as described above; 5 µl of each resulting DNA solution was
added to 50 µl of a mixture of lysis and neutralization reagents (1:1
[vol/vol]). After being mixed, 50 µl was added to 50 µl of the
master mix.
In-house PCR.
An IS6110-based PCR was performed
with primers developed by Kolk et al. (18). The reaction
mixture was modified to prevent amplicon carryover by adding
uracil-N-glycosylase (UNG) and using dUTP instead of dTTP
(21). In brief, after treatment of the specimens as
described above, a PCR with primers INS1
(5'-CGTGAGGGCATCGAGGTGGC-3') and INS2
(5'-GCGTAGGCGTCGGTGACAAA-3') was performed. The reaction mixture (final volume, 50 µl) consisted of 0.067 M Tris-HCl (pH 8.8), 0.016 M ammonium sulfate, 0.01 M 2-mercaptoethanol, 0.02% (wt/vol) gelatin, 3 mM MgCl2, 1 U of Taq
polymerase (Pharmacia, Freiburg, Germany) per 50 µl, 1 U of UNG
(Boehringer Mannheim, Mannheim, Germany) per 50 µl, 200 µM dGTP,
200 µM dATP, 200 µM dCTP, 600 µM dUTP, and 0.5 µM each primer
(final concentrations). The temperature profile consisted of an initial
20 min at 25°C and then an initial denaturation step at 95°C for 10 min, followed by 40 cycles at 94°C for 30 s (denaturation),
65°C for 30 s (annealing), and 72°C for 1 min (extension).
After completion of the amplification reaction the temperature was set
to 72°C until the reaction vessels were removed from the thermal
cycler and immediately chilled on ice. Five microliters of the reaction
mixture was further analyzed by agarose gel electrophoresis and
Southern blotting according to standard protocols. A DNA probe labelled
with digoxigenin (DIG) as described in the following paragraph was used
for hybridization, and a commercially available kit (DIG DNA
luminescent kit; Boehringer Mannheim) was used for detection. All
recommendations of the manufacturer were strictly followed, except that
a ready-for-use hybridization solution (QuickHyb; Stratagene,
Heidelberg, Germany) was used. The complete PCR working area was
organized according to standard recommendations, including separation
of the entire workspace into three distinct areas, use and frequent
change of gloves, and use of disposable filter pipette tips. Inhibition
testing was carried out by adding 10,000 molecules of amplicons
generated with INS1 and INS2 to the reaction mixture and performing the PCR in the same run as the unspiked reaction. Inhibition testing was
performed retrospectively only on culture-positive samples where the
in-house PCR failed to detect M. tuberculosis DNA.
Preparation of the probe for the in-house PCR.
Approximately
104 copies of amplification product obtained with the
primers INS1 and INS2 were subjected to 40 amplification cycles with
primers pt3 (5'-GAACGGCTGATGACCAAACT-3') and pt6
(5'-ACGTAGGCGAACCCTGCCCA-3'). The reaction conditions were
the same as described above for primers INS1 and INS2 except that the
UNG was omitted and all of the dUTP was replaced by 150 µM dTTP and
50 µM DIG-dUTP. After completion of the PCR, the reaction mixtures
were stored at 4°C; 5-µl samples were used as probes without any
further purification in 5 ml of hybridization buffer.
PCR by CA.
After adding 50 µl of sample to 50 µl of the
master mix, PCR amplification tubes were closed and the amplification
ring was transferred into the CA amplification system. One positive and one negative control per vessel ring (12 vessels) provided with the kit
were included in each run. The CA automates the amplification and
detection procedure for PCR. It should be noted that the CA uses a UNG
carryover prevention system (21) and a coamplified internal
control (50 targets per reaction). For discrimination between positive
and negative results, the results were calculated by the CA software
with the cutoff set to an optical density at 650 nm of 0.35.
Handling of discrepant results and definition of an adapted gold
standard.
Specimens with discrepant results by any of the PCR
techniques were retested by the same system; however, we used the
primary results for calculating sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively).
False-negative specimens by in-house PCR were tested for inhibition as
outlined above, and the isolated strains were directly subjected to
in-house PCR in serial 10-fold dilutions to detect
IS6110-negative strains. A discrepant positive PCR result
was considered a true positive if one or more of the following criteria
were met: (i) the sample originated from a patient from whom other
samples were culture positive, (ii) the sample originated from a
patient under successful therapy for TB (iii) the specimen was positive
by both PCR methods, and (iv) the patient's clinical history, chest
roentgenograms, and actual clinical presentation were sufficiently
indicative of TB for an empirical antituberculous therapy.
Additionally, all culture-negative, smear-positive specimens from
patients with culture-proven TB were regarded true DNA positives. A
positive culture result was defined as a false positive if the specimen was negative by both PCR methods and there was no clinical or further
laboratory evidence of TB for the corresponding patient. All patients'
medical records were reviewed as far as possible.
Assessment of the number of specimens necessary for diagnosis of
smear-negative TB patients by CA.
For this analysis, we included
from smear-negative TB patients only specimens from the individual site
of infection drawn before initiation of therapy. Specimens were ordered
by their time of receipt and sequentially numbered, and the number of
sequential specimens that had to be tested until CA gave a positive
result was determined.
 |
RESULTS |
Culture and acid-fast stain.
Of 1,681 specimens tested, 154 (9.16%) were inhibitory for CA and thus were not further regarded for
calculation of sensitivity, specificity, and predictive values. From
the remaining 1,527 specimens from 833 patients, 65 samples from 27 patients were culture positive for M. tuberculosis and 10 samples from 4 patients grew MOTT (these samples were considered
culture negative with regard to growth of M. tuberculosis).
Thirty-five of the culture-positive samples were also smear positive
(53.8%, of which 28 samples were culture positive for M. tuberculosis and 7 samples exhibited MOTT). Thirteen samples were
positive by acid-fast stain but negative by culture; of these, four
were from patients under antituberculous therapy, three were from
patients under therapy for MOTT infection, and six were considered
unspecific positive smear results, because they were negative by both
PCR systems (Fig. 1). For
culture-positive specimens, the average turnaround time was 14.9 days.
From the above data, levels of prevalence of 4.25% for M. tuberculosis and 0.65% for MOTT were calculated. These figures
are representative for all of the specimens examined by conventional
methods in our laboratory (approximately 4,500 to 5,000 samples per
year).
Comparison of CA and in-house PCR with culture.
Of 65 culture-positive samples, 50 were positive by CA (sensitivity, 76.92%;
NPV, 98.97%) and 59 were positive by in-house PCR (sensitivity,
90.76%; NPV, 99.58%). Fifteen culture-positive samples were missed by
CA, and six culture-positive samples were missed by in-house PCR.
Twenty-one culture-negative samples were positive by CA (specificity,
98.56%; PPV, 70.42%), and 35 culture-negative samples were positive
by in-house PCR (specificity, 97.60%; PPV, 62.72%). Of 32 specimens
with a positive smear result, CA detected 27 of 28 culture-positive
samples (sensitivity, 96.42%; NPV, 96.42%) and in-house PCR detected
all of them (sensitivity, 100%; NPV, 100%). If only smear-negative
samples are considered, the figures are as follows: 23 of 37 culture-positive samples were correctly identified as positive by CA
(sensitivity, 62.16%; NPV, 99.03%) and 31 were correctly identified
as positive by in-house PCR (sensitivity, 83.78%; NPV, 99.58%).
Fourteen culture-positive samples were missed by CA, and six were
missed by in-house PCR. There were 20 discordantly positive results by
CA (specificity, 98.62%; PPV, 53.48%) and 32 dis cordantly positive
results by in-house PCR (specificity, 97.80%; PPV, 46.20%) (Table
1).
Resolving discordant results.
Fifteen of 21 discordantly
positive CA samples originated from patients with culture-proven TB,
and 2 discordantly positive results could be confirmed by in-house PCR.
The remaining four discrepantly positive CA results were obtained from
patients 3, 58, 88, and 254. Patient 3 was a 4-month-old infant
admitted to the hospital with an acute severe respiratory infection.
Standard microbiological examination of pharyngeal swabs and nasal
aspirates revealed an infection with respiratory syncythial virus. In
consideration of this result, the age of the patient, and the baby's
clinical presentation, a clinically relevant infection with M. tuberculosis was considered highly improbable and the positive CA
result from one gastric aspirate was considered a false positive.
Patient 58 was a 31-year-old woman with notoriously frequent episodes of spontaneous staphylococcal abscesses. During the course of the study
she was admitted to the hospital for a cesarean section; immediately
thereafter she developed a paraspinal abscess at the fourth cervical
vertebra causing progressive tetraplegia. Two independently drawn
abscess aspirates revealed Staphylococcus aureus, and
consequently, the positive CA result from one of the abscess aspirates
was therefore considered a false positive. From patient 88 only one pus
swab obtained upon lung surgery was submitted; bronchial carcinoma was
suspected. The positive CA result was considered false positive,
because there were no further data available supporting a history of TB
for this patient. From patient 254 only one sputum sample was
available; the clinical diagnosis was atypical pneumonia. This patient
had a high titer of antibody against Coxiella burnetii by
complement fixation (1:80), thus making rickettsial pneumonia probable.
Consequently, we considered the positive CA result false. Taken
together, four positive CA results could not be confirmed by either
laboratory or clinical data and were considered false positives
according to the criteria set forward in Materials and Methods (Table
2).
For in-house PCR, there were 35 discordantly positive results.
Thirty-one of these originated from patients with culture-proven TB,
two were confirmed by CA, and two were obtained from patients 57 and
253. Patient 57 was a 56-year-old woman who was hospitalized with
diffuse abdominal pain. Standard imaging techniques revealed multiple
retroperitoneal abscesses. Several specimens from these abscesses
obtained upon surgery were examined; histological examination suggested
actinomycosis. However, no pathogen could be cultivated despite intense
efforts with a broad spectrum of culture media and culturing
conditions. The patient recovered during a prolonged stay at the
hospital under broad antibiotic therapy with
-lactams and
aminoglycosides. The final success of conventional antibiotic therapy
led us to consider the positive in-house PCR result for one of the
abscess specimens a false positive. Patient 253 was a 4-year-old boy
with frequent episodes of pulmonary infections with common pathogens
due to known multiple atelectases; there had never been any clinical
suspicion of TB. According to the criteria outlined in Materials and
Methods, the positive PCR result for one tracheal aspirate was
considered false positive. Additionally, one smear-positive,
culture-negative specimen from a patient with a previous series of
smear-positive specimens growing M. tuberculosis was
considered a true positive. None of the culture-positive and PCR-negative samples could be considered a false-positive culture result.
Comparison of CA and in-house PCR with the extended gold
standard.
After resolution of discrepantly positive results, 101 samples had to be considered true DNA positives. Of these, the 67 recognized by CA gave a sensitivity of 66.33% and an NPV of 97.66%
and the 92 samples recognized by in-house PCR gave a sensitivity of
91.08% and an NPV of 99.37%. From the remaining four unconfirmed
positive CA results, a specificity of 99.71% and a PPV of 94.36%
could be calculated. The corresponding figures for the in-house PCR were 99.85% for specificity and 97.87% for the PPV. For
smear-positive samples, the sensitivity of CA was 87.5% and the
sensitivity of the in-house PCR was 96.87%. Because there were no
DNA-negative, smear-positive samples by definition, the specificities
of both PCR techniques could not be calculated. If only smear-negative samples were considered, CA recognized 39 of 69 DNA-positive samples (sensitivity, 56.52%; NPV, 97.93%) and in-house PCR recognized 61 of
these (sensitivity, 88.40%; NPV, 99.44%). The unconfirmed CA and
in-house PCR results (four and two samples, respectively) mentioned
above gave specificities of 99.71 and 99.85% and PPV of 90.69 and
96.82%, respectively (Table 3).
Dependence of sensitivity on different types of specimens.
One
aim of this study was to evaluate the sensitivity of CA when it was
applied to specimen types other than sputum. The sensitivities of CA
and in-house PCR compared to that of culture are shown in Table
4 and demonstrate that CA performed even
better with gastric aspirates (sensitivity 70.00% with smear-negative
samples) than with respiratory specimens (sensitivity, 45.45% with
smear-negative samples). This effect was also observed with in-house
PCR (90.00 versus 63.63%, respectively). For other specimen types the
number of culture-positive samples was too low for a valid analysis; however, the data indicate that CA may also be suited for use on urine
specimens (sensitivity, 100%).
Correlation between specimen type and inhibition of PCR.
A
total of 154 specimens were inhibitory to the CA system (9.16%). Among
these 154 samples were 9 culture-positive samples which would thus have
been missed by CA; however, because multiple samples were examined from
the same patient, no positive patient was missed because of PCR
inhibition. When inhibition rates were calculated for individual
specimen types (Table 5), sputum and gastric aspirates exhibited the highest inhibitory potential (10.71 and
12.71%, respectively). The inhibition rates for all other specimen
types ranged between 2.54 and 7.37%. Among the six results falsely
negative by in-house PCR, there were no inhibitory samples; however, it
should be noted here that inhibition testing for the in-house PCR
detects only complete inhibition; strains isolated from these samples
exhibited a strong positive signal when they were tested directly by
in-house PCR, indicating that none of these strains was
IS6110 negative.
Patient-oriented analysis of the diagnostic value of in-house PCR
and CA.
Among the 833 patients enrolled in this study, 46 exhibited positive results by at least one of the investigated methods. Four patients had already been diagnosed with TB at entry into this
study by conventional methods and therefore cannot be considered in
this paragraph. The roles of the two PCR systems for the diagnosis of
the remaining 42 patients are summarized in Table
6.
For four smear-positive patients with MOTT infections, an infection
with M. tuberculosis could be excluded by either PCR system; one of these four patients was not human immunodeficiency virus positive and presented with clinical signs typical of pulmonary TB. The
negative PCR results gave the decisive clue for correct anti-MOTT
therapy. For four additional patients with unspecific positive smear
results, TB could also be ruled out by either PCR technique. This
decision was essential for one of these patients, for whom an already
initiated unnecessary antituberculous therapy could be withdrawn. All
of the 17 smear-positive TB cases included in this study could be
confirmed by either PCR system. Of the 11 smear-negative TB patients, 7 (including 2 culture-negative patients) were diagnosed by either PCR
system before positive culture results were available, and 4 patients
were diagnosed first by in-house PCR (including 3 patients whose TB was
missed by CA). No case was missed by in-house PCR. CA and in-house PCR gave false-positive results for four and two patients, respectively. Because CA results were not given to our clinical colleagues, we cannot
estimate retrospectively if unnecessary therapy would have been
initiated. The two unconfirmed positive in-house PCR results did not
induce initiation of antituberculous therapy after the corresponding
cases had been thoroughly discussed with the clinical colleagues.
Number of specimens necessary for diagnosis of smear-negative TB
patients by CA.
Of the 11 smear-negative TB patients enrolled in
this study, 6 could be identified by CA by testing two specimens; for
an additional 2 patients, testing of 7 and 8 specimens was necessary. The conditions of three remaining patients were missed by CA (for more
details, see Table 7). If the level of
bacterial shedding (as assessed from the rate of true-positive
specimens) is correlated with the number of CA testings necessary for a
diagnosis, it can be demonstrated that all patients with 100%
true-positive specimens except one (patient 354) could be diagnosed by
testing two specimens with CA. For patients with lower bacterial counts
(as concluded from the low rate of true-positive specimens), the number
of necessary CA testings was seven or more; however, there were too few
patients for an extact estimation.
 |
DISCUSSION |
The available data about the CA test show an almost 100%
correlation of this test with the manually performed test
(17), so it is justified in our view to compare our data
with research evaluating the manually performed Amplicor MTB test,
which has been extensively studied during the last few years
(2-4, 7, 8, 10, 11-13, 16, 20, 24, 27, 29). Although a
wide range of sensitivity has been reported for the manual Amplicor MTB
test, most publications reporting investigations of more than 500 specimens and providing separate data for smear-negative samples demonstrate a sensitivity below 66% (D'Amato et al.
[10], 51.2%; Cartuyvels et al. [8],
46%; Carpentier et al. [7], 76%; Moore and Curry
[20], 66%; Bennedsen et al. [3],
60.9%; Bergmann and Woods [4], 40%; Wobeser et al.
[29], 53%). Our data show a similar sensitivity for
the CA test, indicating that this test works with a diagnostic
efficiency comparable to that of the manually performed Amplicor MTB
test. Bodmer et al. (5) have reported an overall sensitivity
of 92.6% for the new CA relative to that of culture; however, 95.6%
of all culture-positive samples were also smear positive. Although the
sensitivity for the smear-negative samples is not explicitly given in
the report of Bodmer et al. (5), the mean optical density
for these samples was 0.01 (cutoff; 0.35), strongly suggesting that
most of the culture-positive and smear-negative samples were negative
by CA. The figures for our in-house PCR are in agreement with those of
previously published reports comparing IS6110-based PCRs
with culture in a large-scale format (6, 19, 24). In
summary, these data indicate a lack of sensitivity for the Roche CA in
comparison to the in-house PCR. The reasons for this might be as
follows. (i) CA uses a single-copy gene as a target, whereas
IS6110-based PCRs use a multiple-copy gene, which increases
sensitivity. Of course, IS6110-based PCRs run a certain risk
of missing M. tuberculosis strains lacking this insertion
element. (ii) A larger sample volume was used for in-house PCR than for
CA (1.0 versus 0.1 ml); however, the final volumes of DNA extract
introduced into the amplification reaction were the reverse (5 µl for
in-house PCR versus 50 µl for CA). As dilution effects varied with
the sediment volume obtained by the extraction protocol for the
in-house PCR, the impact of the larger sample volume on the in-house
PCR cannot definitely be estimated. (iii) Competition could have
suppressed amplification of mycobacterial DNA if it was present at
concentrations far below the concentration of the internal control.
(iv) The CA uses an enzyme-linked immunosorbent assay-based detection
system, which is less sensitive than Southern blotting. In summary, the
issues discussed above make it reasonable that the sensitivity of the CA was found to be lower than that of the in-house PCR, mainly for
reasons related to the basic concept of the test.
The relatively high rate of inhibition of CA may be caused by the use
of DTT for liquefaction of samples, as this method is not approved by
the manufacturer; however, this is only speculative because we have not
directly compared the results of use of DTT with the results of use of
the approved liquefier (N-acetyl-cysteine-NaOH). Data
indicating that use of benzalkonium chloride for decontamination decreases the sensitivity of the manually performed Roche Amplicor MTB
test have been published (8, 19); however, for the present study we separated liquefaction and decontamination into two steps and
performed PCR directly after liquefaction so that there was no
benzalkonium chloride present in the samples analyzed by PCR. Interestingly, Cartuyvels et al. (8), who reported 46%
sensitivity for the manually performed Amplicor assay with
smear-negative specimens, also used benzalkonium chloride for
decontamination of samples before culture but not for PCR; consequently
the low sensitivity of PCR could also be a result of a relatively high sensitivity of culture resulting from a better yield of viable tubercle
bacilli by the Zephirol-trisodium phosphate procedure (23).
We want to point out here that the specificities of both PCR methods
never raised concern for clinical practice. Although the PPV of both
methods were not 100%, no unnecessary therapy was initiated in
response to PCR. Additionally, 8 of 26 smear-positive patients could be
rapidly identified as having non-TB conditions and inappropriate
treatment could be prevented. When we considered the cases where PCR
made an essential contribution to rapid confirmation of positive smear
results (17 of 28 confirmed TB cases) or rapid identification of
smear-negative TB cases (in-house PCR, 11 of 28 confirmed TB cases; CA,
8 of 28 confirmed TB cases), the diagnostic benefit of either method by
far outweighed the problems arising from unconfirmable positive PCR
results.
One aim of this study was also to evaluate the performance of the CA
with nonrespiratory specimens. Although there have been publications
reporting a lower sensitivity of the manually performed Amplicor MTB
for gastric aspirates than for respiratory specimens (11),
in this study the sensitivity of CA with gastric aspirates compared to
that of culture was even higher than its sensitivity with respiratory
specimens. This finding may be explained by (i) a lower viscosity of
gastric aspirates than sputa, increasing the yield of bacterial cells
by centrifugation; (ii) high sample volumes (above 20 ml); and (iii) a
high portion of bacterial cells killed by gastric acid that thus
decreases the sensitivity of culture. Although we used different DNA
extraction procedures for respiratory specimens and gastric aspirates
(alkaline lysis versus washing plus ultrasonication), this does not
seem to have played a major role in the better sensitivity of CA with
gastric aspirates, because our in-house PCR also exhibited better
sensitivity with gastric aspirates. However, for in-house PCR there
were no differences in DNA extraction procedures for respiratory
specimens and gastric aspirates.
If the three cases completely missed by CA are considered, it can be
stated that all three samples (from three patients) probably contained
low bacterial counts, as could be concluded from the fact that only the
liquid media became positive after a prolonged period of incubation
(>4 weeks). In addition, two of the three specimens were biopsies, so
there might not have been an even splitting of the samples. Six of the
8 smear-negative TB patients identified by CA were recognized by
testing one or two specimens; from this we conclude (also with regard
to the overall sensitivity of CA) that testing three samples per
patient with CA is a minimum requirement for smear-negative patients.
Of course, this will identify only patients with considerable bacterial
counts; in cases of lower numbers of bacteria, excessive CA testing may
be required. For these cases, we cannot give any concrete
recommendation based on our data, however.
Although DNA extraction still absorbs the major portion of the manpower
involved, CA offers significant advantages with regard to the amount of
hands-on time required after DNA extraction, compared to that of the
manually performed Amplicor MTB test or our nonautomated in-house
protocol. The possibility of running the system overnight made it
possible to provide results at least by the morning after specimen
receipt. However, as the sensitivity with smear-negative specimens is
not satisfactory in our view, we recommend the use of this test only in
addition to conventional methods (i) for identification of members of
the M. tuberculosis complex in smear-positive specimens and
(ii) with smear-negative specimens, only if a minimum of three samples
from the same patient can be tested.
 |
ACKNOWLEDGMENTS |
We thank Annette Bauer, Monika Amrhein, and Martina Schwer for
excellent technical assistance. We thank Roche Diagnostics for
supplying the CA reagents and the CA system.
 |
FOOTNOTES |
*
Corresponding author. Present address:
Westfälische Wilhelms-Universität, Institut für
Medizinische Mikrobiologie, Klinische Virologie, von Stauffenbergstr.
36, 48151 Münster, Germany. Phone: (49) 251-7793-0. Fax: (49)
251-7793-104. E-mail: eingb{at}uni-muenster.de.
 |
REFERENCES |
| 1.
|
Abe, C.,
K. Hirano,
M. Wada,
Y. Kazumi,
M. Takahashi,
Y. Fukasawa,
T. Yoshimura,
C. Miyagi, and S. Goto.
1993.
Detection of Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and Gen-Probe Amplified Mycobacterium tuberculosis Direct Test.
J. Clin. Microbiol.
31:3270-3274[Abstract/Free Full Text].
|
| 2.
|
Beavis, K. G.,
M. B. Lichty,
D. L. Jungkind, and O. Giger.
1995.
Evaluation of Amplicor PCR for direct detection of Mycobacterium tuberculosis from sputum specimens.
J. Clin. Microbiol.
33:2582-2586[Abstract].
|
| 3.
|
Bennedsen, J.,
V. O. Thomsen,
G. E. Pfyffer,
G. Funke,
K. Feldman,
A. Beneke,
P. A. Jenkins,
M. Hegginbothom,
A. Fahr,
M. Hengstler,
G. Cleator,
P. Klapper, and E. G. L. Wilkins.
1996.
Utility of PCR in diagnosing pulmonary tuberculosis.
J. Clin. Microbiol.
34:1407-1411[Abstract].
|
| 4.
|
Bergmann, J. S., and G. L. Woods.
1996.
Clinical evaluation of the Roche AMPLICOR PCR Mycobacterium tuberculosis test for detection of M. tuberculosis in respiratory specimens.
J. Clin. Microbiol.
34:1083-1085[Abstract].
|
| 5.
|
Bodmer, T.,
A. Gurtner,
M. Scholkmann, and L. Matter.
1997.
Evaluation of the COBAS AMPLICOR MTB system.
J. Clin. Microbiol.
35:1604-1605[Abstract].
|
| 6.
|
Brisson-Noel, A.,
C. Aznar,
C. Chureau,
S. Nguyen,
C. Pierre,
M. Bartoli,
R. Bonete,
G. Pialoux,
B. Gicquel, and G. Garrigue.
1991.
Diagnosis by DNA amplification in clinical practice evaluation.
Lancet
338:364-366[Medline].
|
| 7.
|
Carpentier, E.,
B. Drouillard,
M. Dailloux,
D. Moinard,
E. Vallee,
B. Duthilh,
J. Maugein,
E. Bergogne-Berezin, and B. Carbonnelle.
1995.
Diagnosis of tuberculosis by Amplicor Mycobacterium tuberculosis test: a multicenter study.
J. Clin. Microbiol.
33:3106-3110[Abstract].
|
| 8.
|
Cartuyvels, R.,
C. de Ridder,
S. Jonckheere,
L. Verbist, and J. van Eldere.
1996.
Prospective clinical evaluation of Amplicor Mycobacterium tuberculosis PCR test as a screening method in a low-prevalence population.
J. Clin. Microbiol.
34:2001-2003[Abstract].
|
| 9.
|
Clarridge, J. E., III,
R. M. Shawar,
T. M. Shinnick, and B. B. Plikaytis.
1993.
Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory.
J. Clin. Microbiol.
31:2049-2056[Abstract/Free Full Text].
|
| 10.
|
D'Amato, R. P.,
A. A. Wallman,
L. H. Hochstein,
P. M. Colannino,
M. Scardamaglia,
E. Ardila,
M. Ghouri,
K. Kim,
R. C. Patel, and A. Miller.
1995.
Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test.
J. Clin. Microbiol.
33:1832-1834[Abstract].
|
| 11.
|
Devallois, A.,
E. Legrand, and N. Rastogi.
1996.
Evaluation of Amplicor MTB test as adjunct to smears and culture for direct detection of Mycobacterium tuberculosis in the French Caribbean.
J. Clin. Microbiol.
34:1065-1068[Abstract].
|
| 12.
|
Dilworth, J. P.,
M. Goyal,
D. B. Young, and R. J. Shaw.
1996.
Comparison of polymerase chain reaction for IS 6110 and Amplicor in the diagnosis of tuberculosis.
Thorax
51:320-322[Abstract].
|
| 13.
|
Doucet-Populaire, F.,
V. Lalande,
B. Carpentier,
A. Bourgoin,
M. Dialloux,
C. Bollet,
A. Vachee,
D. Moinard,
J. Texier-Maugein,
B. Carbonnelle, and J. Grosset.
1996.
A blind study of the polymerase chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group.
Tubercle Lung Dis.
77:358-362[Medline].
|
| 14.
|
Eisenach, K. D.,
M. D. Sifford,
M. D. Cave,
J. H. Bates, and J. T. Crawford.
1991.
Detection of Mycobacterium tuberculosis in sputum samples using a polymerase chain reaction.
Am. Rev. Respir. Dis.
144:1160-1163[Medline].
|
| 15.
|
Hermans, P. M. W.,
A. R. J. Schuitema,
D. Van Soolingen,
C. P. H. J. Verstynen,
E. M. Bik,
J. E. R. Thole,
A. H. J. Kolk, and J. D. A. van Embden.
1990.
Specific detection of Mycobacterium tuberculosis complex strains by polymerase chain reaction.
J. Clin. Microbiol.
28:1204-1213[Abstract/Free Full Text].
|
| 16.
|
Huang, T.-S.,
Y.-C. Liu,
H.-H. Lin,
W.-K. Huang, and D.-L. Cheng.
1996.
Comparison of the Roche AMPLICOR MYCOBACTERIUM assay and Digene SHARP Signal System with in-house PCR and culture for detection of Mycobacterium tuberculosis in respiratory specimens.
J. Clin. Microbiol.
34:3092-3096[Abstract].
|
| 17.
|
Jungkind, D.,
S. DiRenzo,
K. G. Beavis, and N. S. Silverman.
1996.
Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management.
J. Clin. Microbiol.
34:2778-2783[Abstract].
|
| 18.
|
Kolk, A. H. J.,
A. R. J. Schuitema,
S. Kuijper,
P. W. M. Hermans,
J. D. A. van Embden, and R. A. Hartskeerl.
1992.
Detection of Mycobacterium tuberculosis in clinical samples by using polymerase chain reaction and a nonradioactive detection system.
J. Clin. Microbiol.
30:2567-2575[Abstract/Free Full Text].
|
| 19.
|
Lalande, V.,
F. Doucet-Populaire,
R. Chataigne,
J. C. Ghnassia, and J. C. Petit.
1996.
Comparison of two decontamination methods for direct detection by PCR of Mycobacterium tuberculosis from smear-positive specimens. Poster abstract at the Cinquièmes Journées de Mycobactériologie de Langue Francaise, Nice, France, 6 to 7 November 1996
.
|
| 20.
|
Moore, D. F., and J. I. Curry.
1995.
Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by Amplicor PCR. 1995.
J. Clin. Microbiol.
33:2686-2691[Abstract].
|
| 21.
|
Persing, D. H., and G. D. Cimino.
1993.
Amplification product inactivation methods, p. 105-121.
In
D. H. Persing, T. F. Smith, F. C. Tenover, and T. J. White (ed.), Diagnostic molecular microbiology: principles and applications. American Society for Microbiology, Washington, D.C.
|
| 22.
|
Pfyffer, G. E.,
P. Kissling,
R. Wirth, and R. Weber.
1994.
Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system.
J. Clin. Microbiol.
32:918-923[Abstract/Free Full Text].
|
| 23.
|
Roberts, G. D.,
E. W. Koneman, and Y. K. Kim.
1991.
Mycobacterium, p. 304-339.
In
A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
|
| 24.
|
Schirm, J.,
L. A. B. Oostendorp, and J. G. Mulder.
1995.
Comparison of Amplicor, in-house PCR, and conventional culture for detection of Mycobacterium tuberculosis in clinical samples.
J. Clin. Microbiol.
33:3221-3224[Abstract].
|
| 25.
|
Shah, J. S.,
J. Liu,
D. Buxton,
A. Hendricks,
L. Robinson,
G. Radcliffe,
W. King,
D. Lane,
D. M. Olive, and J. D. Klinger.
1995.
Q-Beta replicase-amplified assay for detection of Mycobacterium tuberculosis directly from clinical specimens.
J. Clin. Microbiol.
33:1435-1441[Abstract].
|
| 26.
|
Sjöbring, U.,
M. Mecklenburg,
A. B. Andersen, and H. Miorner.
1990.
Polymerase chain reaction for detection of Mycobacterium tuberculosis.
J. Clin. Microbiol.
28:2200-2204[Abstract/Free Full Text].
|
| 27.
|
Stauffer, F.,
R. Mutschlechner,
P. Hasenberger,
S. Stadlbauer, and H. Schinko.
1995.
Detection of Mycobacterium tuberculosis complex in clinical specimens by a commercial polymerase chain reaction kit.
Eur. J. Clin. Microbiol. Infect. Dis.
14:1046-1051[Medline].
|
| 28.
|
Telenti, A.,
F. Marchesi,
M. Balz,
F. Bally,
E. C. Böttger, and T. Bodmer.
1993.
Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.
J. Clin. Microbiol.
31:175-178[Abstract/Free Full Text].
|
| 29.
|
Wobeser, W. L.,
M. Krajden,
J. Conly,
H. Simpson,
B. Yim,
M. D'Costa,
M. Fuksa,
C. Hian-Cheong,
M. Patterson,
A. Phillips,
R. Bannatyne,
A. Haddad,
J. L. Brunton, and S. Krajden.
1996.
Evaluation of Roche Amplicor PCR assay for Mycobacterium tuberculosis.
J. Clin. Microbiol.
34:134-139[Abstract].
|
Journal of Clinical Microbiology, July 1998, p. 2023-2029, Vol. 36, No. 7
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wang, J.-Y., Lee, L.-N., Hsu, H.-L., Hsueh, P.-R., Luh, K.-T.
(2006). Performance Assessment of the DR. MTBC Screen Assay and the BD ProbeTec ET System for Direct Detection of Mycobacterium tuberculosis in Respiratory Specimens.. J. Clin. Microbiol.
44: 716-719
[Abstract]
[Full Text]
-
Torrea, G., Van de Perre, P., Ouedraogo, M., Zougba, A., Sawadogo, A., Dingtoumda, B., Diallo, B., Defer, M. C., Sombie, I., Zanetti, S., Sechi, L. A
(2005). PCR-based detection of the Mycobacterium tuberculosis complex in urine of HIV-infected and uninfected pulmonary and extrapulmonary tuberculosis patients in Burkina Faso. J Med Microbiol
54: 39-44
[Abstract]
[Full Text]
-
Wang, J.-Y., Lee, L.-N., Chou, C.-S., Huang, C.-Y., Wang, S.-K., Lai, H.-C., Hsueh, P.-R., Luh, K.-T.
(2004). Performance Assessment of a Nested-PCR Assay (the RAPID BAP-MTB) and the BD ProbeTec ET System for Detection of Mycobacterium tuberculosis in Clinical Specimens. J. Clin. Microbiol.
42: 4599-4603
[Abstract]
[Full Text]
-
Piersimoni, C., Scarparo, C.
(2003). Relevance of Commercial Amplification Methods for Direct Detection of Mycobacterium tuberculosis Complex in Clinical Samples. J. Clin. Microbiol.
41: 5355-5365
[Full Text]
-
Honore-Bouakline, S., Vincensini, J. P., Giacuzzo, V., Lagrange, P. H., Herrmann, J. L.
(2003). Rapid Diagnosis of Extrapulmonary Tuberculosis by PCR: Impact of Sample Preparation and DNA Extraction. J. Clin. Microbiol.
41: 2323-2329
[Abstract]
[Full Text]
-
Rimek, D., Tyagi, S., Kappe, R.
(2002). Performance of an IS6110-Based PCR Assay and the COBAS AMPLICOR MTB PCR System for Detection of Mycobacterium tuberculosis Complex DNA in Human Lymph Node Samples. J. Clin. Microbiol.
40: 3089-3092
[Abstract]
[Full Text]
-
Boddinghaus, B., Wichelhaus, T. A., Brade, V., Bittner, T.
(2001). Removal of PCR Inhibitors by Silica Membranes: Evaluating the Amplicor Mycobacterium tuberculosis Kit. J. Clin. Microbiol.
39: 3750-3752
[Abstract]
[Full Text]
-
Watterson, S A, Drobniewski, F A
(2000). Modern laboratory diagnosis of mycobacterial infections. J. Clin. Pathol.
53: 727-732
[Abstract]
[Full Text]
-
Lim, T. K., Gough, A., Chin, N.-K., Kumarasinghe, G.
(2000). Relationship Between Estimated Pretest Probability and Accuracy of Automated Mycobacterium tuberculosis Assay in Smear-Negative Pulmonary Tuberculosis. Chest
118: 641-647
[Abstract]
[Full Text]
-
Scarparo, C., Piccoli, P., Rigon, A., Ruggiero, G., Scagnelli, M., Piersimoni, C.
(2000). Comparison of Enhanced Mycobacterium tuberculosis Amplified Direct Test with COBAS AMPLICOR Mycobacterium tuberculosis Assay for Direct Detection of Mycobacterium tuberculosis Complex in Respiratory and Extrapulmonary Specimens. J. Clin. Microbiol.
38: 1559-1562
[Abstract]
[Full Text]
-
Hanna, B. A., Ebrahimzadeh, A., Elliott, L. B., Morgan, M. A., Novak, S. M., Rusch-Gerdes, S., Acio, M., Dunbar, D. F., Holmes, T. M., Rexer, C. H., Savthyakumar, C., Vannier, A. M.
(1999). Multicenter Evaluation of the BACTEC MGIT 960 System for Recovery of Mycobacteria. J. Clin. Microbiol.
37: 748-752
[Abstract]
[Full Text]
-
Garrino, M. G., Glupczynski, Y., Degraux, J., Nizet, H., Delmée, M.
(1999). Evaluation of the Abbott LCx Mycobacterium tuberculosis Assay for Direct Detection of Mycobacterium tuberculosis Complex in Human Samples. J. Clin. Microbiol.
37: 229-232
[Abstract]
[Full Text]